192 related articles for article (PubMed ID: 1329613)
1. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
[TBL] [Abstract][Full Text] [Related]
2. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
[TBL] [Abstract][Full Text] [Related]
7. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
[TBL] [Abstract][Full Text] [Related]
8. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
Entenza JM; Marchetti O; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
[TBL] [Abstract][Full Text] [Related]
12. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Maserati R; Cagni AE; Segú C
Chemotherapy; 1996; 42(2):133-9. PubMed ID: 8697888
[TBL] [Abstract][Full Text] [Related]
13. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Hessen MT; Pitsakis PG; Kaye D
Antimicrob Agents Chemother; 1990 Jun; 34(6):1143-5. PubMed ID: 2393273
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Barriere SL; Schaberg DR; Fekety R
Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569
[TBL] [Abstract][Full Text] [Related]
16. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Barriere SL; Schaberg DR; Fekety R
J Antimicrob Chemother; 1987 Nov; 20(5):753-8. PubMed ID: 3429376
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
Antimicrob Agents Chemother; 1998 Apr; 42(4):981-3. PubMed ID: 9559828
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
Antimicrob Agents Chemother; 1990 Feb; 34(2):257-60. PubMed ID: 2327773
[TBL] [Abstract][Full Text] [Related]
19. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.
Chambers HF; Hackbarth CJ; Drake TA; Rusnak MG; Sande MA
J Infect Dis; 1984 Jun; 149(6):894-903. PubMed ID: 6564133
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
Fernandez-Guerrero M; Rouse M; Henry N; Wilson W
Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
